Sumitomo Chemical Company, Limited

Consolidated sales revenue for Q1 FY2026 was JPY 578.2 billion, up JPY 52.1 billion year on year. Core operating income was JPY 62.3 billion, up JPY 34.7 billion year on year, and operating income was JPY 61 billion, up JPY 35.6 billion. Net income attributable to owners of the parent was JPY 40.8 billion, up JPY 45.3 billion; finance income and expenses were a loss of JPY 700 million, improving by JPY 18.9 billion year on year, and income tax expense was JPY 9 billion. Segment highlights included Agro and Life Solutions at JPY 9.6 billion core operating income, ICT & Mobility Solutions at JPY 13 billion, Advanced Medical Solutions at a JPY 1.9 billion core operating loss, Essential and Green Materials at JPY 27.2 billion, and Sumitomo Pharma at JPY 18.8 billion. For the first half of FY2026, management expects sales revenue of JPY 1.17 trillion, core operating income of JPY 125 billion, operating income of JPY 122 billion, and quarterly net income attributable to owners of the parent of JPY 70 billion; the annual dividend remains JPY 16 per share. The company did not revise its full-year forecast, citing uncertainty in the Middle East.

Yamauchi framed the quarter as a strong start to FY2026, emphasizing that profit improved across all segments and that the company achieved its second-best Q1 on record for core operating income and net income. His tone was confident on near-term execution, especially in Agro and Life Solutions and semiconductor-related businesses, but cautious on the second half because geopolitical risk in the Middle East still clouds the outlook. He repeatedly pointed to Petro Rabigh, pricing, and inventory valuation as major drivers of the earnings rebound.

Management highlighted that the D/E ratio improved to 0.80x from 0.93x at FY25 end, helped by Sumitomo Pharma’s JPY 97.8 billion capital increase. The balance sheet expanded, with total assets at JPY 3,613.5 billion, up JPY 208.5 billion, while interest-bearing liabilities fell to JPY 1,132.2 billion and equity rose to JPY 1,412.4 billion. Cash flow from operations was positive JPY 5 billion, free cash flow was negative JPY 44.3 billion, and financing cash flow was positive JPY 55.6 billion, driven by Sumitomo Pharma’s public offering. On margins and earnings drivers, he cited JPY 15 billion of price-driven core operating income benefit, a JPY 23.7 billion volume/equity-method benefit, and temporary inventory valuation gains in Essential and Green Materials.

Analysts pressed management on Agro and Life’s Q2 jump, asking about methionine pricing, crop protection demand, inventory normalization, and El Nino impacts. Yamauchi said Q1 strength came mainly from methionine as Middle East supply-demand tightened, and that Q2 should benefit from crop protection seasonality in Brazil, Latin America, and India, with El Nino creating mixed regional effects. In ICT & Mobility, analysts asked why profit would be relatively flat quarter to quarter despite seasonal demand; management said display should improve somewhat, semiconductors are steady, but higher fixed costs tied to semiconductor-related investments will offset part of the volume benefit. On Essential and Green Materials, management said Q2 should be similar apart from lower inventory valuation gains and higher Petro Rabigh contribution, and noted Singapore utilization is not expected to rise materially for now.